Biomarkers and Antibodies Development for Bladder Cancer

1. Biomarkers and Antibodies Development for Bladder Cancer With years of experience in developing antibodies for analytical research and diagnostic applications, Creative Biolabs specializes in custom antibody and assay development for the diagnosis of a variety of diseases and infections. Particularly, we provide high-quality in vitro diagnosis (IVD) antibody development services for the diagnosis of different cancers, such as bladder cancer. Introduction of Bladder Cancer Bladder cancer is the commonest malignancy of the urinary tract, accounting for 7 percent of all cancers in men and 2 percent of those in women. The main symptoms of bladder cancer include blood in the urine, pain with urination and low back pain. Although the accurate cause remains unclear, risk factors that may contribute to its development include cigarette smoking, occupational exposure to chemicals such as aniline dyes and aromatic amines, consumption of analgesics containing phenacetin, chronic infection or irritation of the bladder, and chemotherapeutic agents such as cyclophosphamide. Over 90% of malignant tumors of the bladder are 'urothelial' transitional cell carcinoma (TCC). Less common forms of bladder cancer include squamous cell carcinoma, adenocarcinoma, and neuroendocrine tumors. The grading and staging of bladder cancer use the TNM (tumor, nodes, metastases) classification system, which provides important information for disease prognosis and prediction. Fig 1. T-stages of transitional cell carcinoma bladder cancer (TNM classification). (Hanna, 2016) Diagnosis of Bladder Cancer

2. The diagnosis and classification of bladder cancer are important to determine the appropriate treatment strategy and predict outcomes. The cornerstone of diagnosis of bladder cancer is the cystoscopic examination of the lower urinary tract, and the white light cystoscopy (WLC) remains the gold standard. Recently, new optical diagnostic methods have been designed to improve the accuracy of WLC: fluorescence cystoscopy, narrow-band imaging, and optical coherence tomography. To identify lesions within the ureter, renal pelvis and renal parenchyma, medical imaging techniques such as ultrasonography, intravenous urogram or computed tomography (CT) may also be applied. Moreover, urine cytology can be a useful test for diagnosing high-grade disease. Diagnostic Tumor Markers Cystoscopy and urine cytology is currently the gold standard in the diagnosis and follow-up of bladder cancer, yet still exhibit limited sensitivity, leading to the development of more advanced tests for the identification and surveillance of bladder cancer, such as the development of diagnostic tumor markers. For example, tumor-associated antigens that can be detected in both voided urine samples and tissue sections have been investigated for their potential diagnostic use. As a result, a number of monoclonal antibodies have been produced and some of them prove to have clinical value. Currently, BTA, BTA stat, BTA trak, NMP22, AccuDx and Immunocyt test are approved by the Food and Drug Administration. These test systems have presented promising capabilities, indicating a higher sensitivity than urine cytology to detect primary and recurrent bladder tumors. Hence, there is reason to believe that in the future, rather highly sensitive tests can be developed and may be able to replace cytology as an adjunct to cystoscopy or to replace cystoscopy itself in the follow-up of selected patients. In order to improve human health globally, Creative Biolabs' mission is to provide extensive expertise in the development of valuable antibodies for diagnostic use to support our clients. We are proud to share this expertise and our state-of-the-art facilities to facilitate their brilliant studies. Moreover, every project can be customized to meet your specific needs. The following links provide the biomarkers and related IVD antibodies used for diagnosis of Bladder Cancer being provided by Creative Biolabs. EGF Resistin Retinoic acid-induced protein 3 Coronin-1A DJ-1/PARK7 Chromosome 7 Chromosome 9p21 Apolipoprotein A1 α subunit of Gs Gamma synuclein Semenogelin-2 Fibrinogen Apolipoprotein A4 Chromosome 3 Nuclear matrix protein 22 Reference

3. 1. Hanna, M. Y., (2016). "Bladder cancer." Medicine, 44.1:52-55. Related Services: IVD Antibodies for Exosome Marker Biomarkers and Antibodies Development for Follicular Adenoma Biomarkers and Antibodies Development for Melanoma Biomarkers and Antibodies Development for Leukemia Biomarkers and Antibodies Development for Testicular Cancer Biomarkers and Antibodies Development for Breast Cancer Biomarkers and Antibodies Development for Pancreatic Cancer Biomarkers and Antibodies Development for Brain Cancer Biomarkers and Antibodies Development for Gastrointestinal Cancer Biomarkers and Antibodies Development for Prostate Cancer Biomarkers and Antibodies Development for Cholangiocarcinoma Biomarkers and Antibodies Development for Germ Cell Cancer Biomarkers and Antibodies Development for Ovarian Cancer Biomarkers and Antibodies Development for Liver Cancer Biomarkers and Antibodies Development for Neuroendocrine Tumor Biomarkers and Antibodies Development for Renal Cancer Biomarkers and Antibodies Development for Lymph Cancer Biomarkers and Antibodies Development for Glioma Biomarkers and Antibodies Development for Esophageal Cancer Biomarkers and Antibodies Development for Myeloma Biomarkers and Antibodies Development for Colorectal Cancer Biomarkers and Antibodies Development for Glioblastoma Biomarkers and Antibodies Development for Thyroid Cancer Biomarkers and Antibodies Development for Lung Cancer